Aptose Biosciences is a clinical-stage biotechnology company developing personalized therapies to address unmet medical needs in oncology, with a particular focus on hematologic malignancies. Aptose is advancing new therapeutics focused on well validated and novel drug targets on the leading edge of cancer research, coupled with validated biomarkers to identify the optimal patient population for our products. The company's small molecule cancer therapeutics pipeline includes products designed for potent single agent activity and to enhance the efficacy of existing anti-cancer therapies without overlapping toxicities. Aptose Biosciences Inc. is listed on NASDAQ under the symbol APTO and on the TSX under the symbol APS.
No articles found.
With demonstrated clinical development and commercialization expertise, VIVUS is d...
With demonstrated clinical development and comm...
Equillium is a biotechnology company leveraging deep understanding of immunobiolog...
Equillium is a biotechnology company leveraging...
IMV Inc. is a clinical stage biopharmaceutical company dedicated to making immunot...
IMV Inc. is a clinical stage biopharmaceutical ...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Exicure, Inc. is a clinical stage biotechnology company developing a new class of ...
Exicure, Inc. is a clinical stage biotechnology...
Ascendis Pharma is applying its innovative technology platform to build a leading,...
Ascendis Pharma is applying its innovative tech...
BioCurity is a clinical stage biopharmaceutical company with a mission to material...
BioCurity is a clinical stage biopharmaceutical...
Rigel Pharmaceuticals, Inc. is a biotechnology company dedicated to discovering, d...
Rigel Pharmaceuticals, Inc. is a biotechnology ...
Join the National Investor Network and get the latest information with your interests in mind.